Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RAI SERVICES COMPANY · Firm: CGCN GROUP, LLC
Issues surrounding prevention of illicit tobacco, patents, tariffs, duty and customs, Free Trade Agreements (FTAs); HR 1, THE ONE BIG BEAUTIFUL BILL
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RAI SERVICES COMPANY · Firm: CGCN GROUP, LLC
Issues surrounding prevention of illicit tobacco, patents, tariffs, duty and customs, Free Trade Agreements (FTAs); HR 1, THE ONE BIG BEAUTIFUL BILL
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
OTW HOLDINGS LLC via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to maternal and infant health.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PARTNER THERAPEUTICS, INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
Source: Senate LDA
| FUJIFILM HOLDINGS AMERICA CORPORATION |
| 13 |
| 2023–2026 |
| C3.AI, INC. | 11 | 2024–2026 |
| CARE SOLACE | 10 | 2024–2026 |
| HIGHLAND ELECTRIC FLEETS | 10 | 2024–2026 |
| U.S. TRAVEL ASSOCIATION | 10 | 2023–2025 |
| TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS | 9 | 2024–2026 |
| VERTEX PHARMACEUTICALS INCORPORATED | 9 | 2024–2026 |
| ALVOGEN, INC. | 8 | 2025–2026 |
| EBAY INC | 8 | 2025–2026 |
| MICROSOFT CORPORATION | 8 | 2023–2025 |
| PARTNER THERAPEUTICS, INC. | 8 | 2025–2026 |
| THE MOTOR & EQUIPMENT MANUFACTURERS ASSOCIATION | 8 | 2025–2026 |
| AMERICAN FREE ENTERPRISE CHAMBER OF COMMERCE | 7 | 2023–2025 |
| BINTI | 7 | 2025–2026 |
| ERADIVIR | 7 | 2024–2025 |
| MANUS BIO INC. | 7 | 2025–2026 |
| POLYMEDCO, LLC. | 7 | 2024–2025 |
| CHANGE & IMPACT INC. | 6 | 2025–2026 |
| Fresenius Kabi USA, LLC | 6 | 2025–2026 |
| OVINTIV, INC. (FKA ENCANA OIL AND GAS (USA), INC.) | 6 | 2023–2024 |
| PARKVIEW HEALTH SYSTEM, INC. | 6 | 2025–2026 |
| REGIONS FINANCIAL CORPORATION | 6 | 2023–2024 |
| RIO TINTO SERVICES, INC. | 6 | 2023–2024 |
| SAMSUNG SEMICONDUCTOR, INC. | 6 | 2023–2024 |
| THE SURETY & FIDELITY ASSOCIATION OF AMERICA | 6 | 2023–2024 |
| UNITED BY INTEREST, ON BEHALF OF HILCORP ENERGY COMPANY | 6 | 2023–2024 |
| DUKE ENERGY CORPORATION | 5 | 2023–2024 |
| ELECTRONIC PAYMENTS COALITION | 5 | 2023–2024 |
| ENTEK TECHNOLOGY HOLDING, LLC | 5 | 2025–2026 |
| EXELON CORPORATION | 5 | 2023–2024 |
| FEDERAL HOME LOAN BANK OF DALLAS | 5 | 2023–2024 |
| GENWORTH FINANCIAL, INC. | 5 | 2023–2024 |
| INVESTMENT COMPANY INSTITUTE | 5 | 2023–2024 |
| LENNOX INTERNATIONAL INC. | 5 | 2023–2024 |
| MASTERCARD WORLDWIDE | 5 | 2023–2024 |
| MEMORA HEALTH | 5 | 2023–2024 |
| NEWS CORPORATION | 5 | 2023–2024 |
| SOLSTICE ADVANCED MATERIALS INC. | 5 | 2025–2026 |
| THE INTERSTATE NATURAL GAS ASSOCIATION OF AMERICA | 5 | 2023–2024 |
| WALT DISNEY COMPANY THE | 5 | 2023–2024 |
| AMERICAN AIRLINES, INC. | 4 | 2023–2024 |
| AMERICAN CHEMISTRY COUNCIL, INC. | 4 | 2023–2024 |
| AMERICAN RETIREMENT ASSOCIATION | 4 | 2023–2024 |
| BANK POLICY INSTITUTE (FKA THE FINANCIAL SERVICES ROUNDTABLE) | 4 | 2023–2024 |
| BEAM INC. (PREVIOUSLY REPORTED AS FORTUNE BRANDS INC.) | 4 | 2023–2024 |
| BLOOMBERG LP | 4 | 2023–2024 |
| BRADFORD WHITE CORPORATION | 4 | 2023–2024 |
| BREAD FINANCIAL (FKA ALLIANCE DATA SYSTEMS CORPORATION) | 4 | 2023–2024 |
| BSA THE SOFTWARE ALLIANCE (FORMERLY BSA BUSINESS SOFTWARE ALLIANCE INC) | 4 | 2023–2024 |
| CHOICE HOTELS INTERNATIONAL, INC. | 4 | 2023–2024 |
| DATAMAXX APPLIED TECHNOLOGIES, INC. | 4 | 2023–2024 |
| HONEYWELL INTERNATIONAL | 4 | 2025 |
| KRAFT HEINZ COMPANY | 4 | 2025 |
| NATIONAL ALLIANCE FOR PUBLIC CHARTER SCHOOLS | 4 | 2023–2024 |
| AMERICAN PETROLEUM INSTITUTE (API) | 3 | 2023 |
| HEARTLAND ACTION | 3 | 2026 |
| INVIVYD, INC. | 3 | 2024 |
| TD BANK, N.A. | 3 | 2023 |
| HEALTHY MOMS, HEALTHY BABIES AMERICA | 2 | 2026 |
| OTW HOLDINGS LLC | 2 | 2026 |
| PFIZER, INC. | 2 | 2023 |
| PHOTOCURE INC. | 2 | 2026 |
| SI GROUP CLIENT SERVICES (FKA SWISHER) | 2 | 2023 |
| ADVAMED | 1 | 2023 |
| MEDLINE INDUSTRIES, LP | 1 | 2023 |
| NATIONAL OILSEED PROCESSORS ASSOCIATION | 1 | 2025 |
| WORTHINGTON INDUSTRIES, INC. | 1 | 2023 |
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RAI SERVICES COMPANY · Firm: CGCN GROUP, LLC
Issues surrounding prevention of illicit tobacco, patents, tariffs, duty and customs, Free Trade Agreements (FTAs); HR 1, THE ONE BIG BEAUTIFUL BILL
Restoring Competitive Property Insurance Availability Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; H.R. 1070 To Exclude from Gross Income Certain Income from Providing Real Property Insurance Following Certain Federally Declared Disasters.
Restoring Competitive Property Insurance Availability Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; H.R. 1070 To Exclude from Gross Income Certain Income from Providing Real Property Insurance Following Certain Federally Declared Disasters.
Litigation Transparency Act of 2025
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Litigation Transparency Act of 2025
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Litigation Transparency Act of 2025
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: CGCN GROUP, LLC
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: CGCN GROUP, LLC
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: CGCN GROUP, LLC
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
REPAIR Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
H.R. 1566 Right to Repair **Issues lobbied without specific bill number:AutonomousVehicles
REPAIR Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
H.R. 1566 Right to Repair **Issues lobbied without specific bill number:AutonomousVehicles
REPAIR Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
H.R. 1566 Right to Repair
Protecting Our Courts from Foreign Manipulation Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Protecting Our Courts from Foreign Manipulation Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Protecting Our Courts from Foreign Manipulation Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Tackling Predatory Litigation Funding Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; H.R. 1070 To Exclude from Gross Income Certain Income from Providing Real Property Insurance Following Certain Federally Declared Disasters.
Tackling Predatory Litigation Funding Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Tackling Predatory Litigation Funding Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Tackling Predatory Litigation Funding Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: TCJA; Issues lobbied without specific bill number: Third Party Litigation Financing Tax on Any Income Derived from that Kind of Litigation Funding; S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; S. 336 To Exclude from Gross Income Amount Received from State-based Catastrophe Loss Mitigation Programs.
Tackling Predatory Litigation Funding Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Tackling Predatory Litigation Funding Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; H.R. 1070 To Exclude from Gross Income Certain Income from Providing Real Property Insurance Following Certain Federally Declared Disasters.
Issues related to AI (artificial intelligence) in the defense industry; H.R. 4016 - Department of Defense Appropriations Act, 2026; S. 2572 Department of Defense Appropriations Act, 2026.
Issues related to AI (artificial intelligence) in the defense industry; H.R. 4016 - Department of Defense Appropriations Act, 2026; S. 2572 Department of Defense Appropriations Act, 2026.
Issues related to AI (artificial intelligence) in the defense industry; H.R. 4016 - Department of Defense Appropriations Act, 2026; S. 2572 Department of Defense Appropriations Act, 2026.
Limiting Liability for Critical Infrastructure Manufacturers Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Limiting Liability for Critical Infrastructure Manufacturers Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Limiting Liability for Critical Infrastructure Manufacturers Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY27 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 Tribal Opioid Response Grant funding for FY27 NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act
Reauthorization of Protecting Americans from All-Hazards Preparedness Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY27 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 Tribal Opioid Response Grant funding for FY27 NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act
Reauthorization of Protecting Americans from All-Hazards Preparedness Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY27 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 Tribal Opioid Response Grant funding for FY27 NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY27 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 Tribal Opioid Response Grant funding for FY27 NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Lawsuit Abuse Reduction Act of 2025
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Lawsuit Abuse Reduction Act of 2025
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Lawsuit Abuse Reduction Act of 2025
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
FAIR Trucking Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
FAIR Trucking Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
FAIR Trucking Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
Protecting TPLF From Abuse Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Protecting TPLF From Abuse Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Protecting TPLF From Abuse Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
TRIA Program Reauthorization Act of 2026
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
H.R. 7128 Terrorism Risk Insurance
TRIA Program Reauthorization Act of 2026
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
H.R. 7128 Terrorism Risk Insurance
TRIA Program Reauthorization Act of 2026
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
H.R. 7128 Terrorism Risk Insurance
Advocacy related to bladder cancer treatment and blue light cystoscopy, H.R. 8032.
Advocacy related to bladder cancer treatment and blue light cystoscopy, H.R. 8032.
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
National Defense Authorization Act for Fiscal Year 2027
Client: EMERGENT BIOSOLUTIONS INC. · Firm: CGCN GROUP, LLC
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Lower Costs, More Transparency Act of 2026
Client: PARKVIEW HEALTH SYSTEM, INC. · Firm: CGCN GROUP, LLC
General health care issues related to hospitals; Lower Costs, More Transparency Act (H.R. 9393).
Lower Costs, More Transparency Act of 2026
Client: PARKVIEW HEALTH SYSTEM, INC. · Firm: CGCN GROUP, LLC
General health care issues related to hospitals; Lower Costs, More Transparency Act (H.R. 9393).
National Defense Authorization Act for Fiscal Year 2026
Client: FUJIFILM HOLDINGS AMERICA CORPORATION · Firm: CGCN GROUP, LLC
S.1071 - National Defense Authorization Act for Fiscal Year 2026.
National Defense Authorization Act for Fiscal Year 2026
Client: FUJIFILM HOLDINGS AMERICA CORPORATION · Firm: CGCN GROUP, LLC
S.1071 - National Defense Authorization Act for Fiscal Year 2026.
National Defense Authorization Act for Fiscal Year 2026
Client: FUJIFILM HOLDINGS AMERICA CORPORATION · Firm: CGCN GROUP, LLC
S.1071 - National Defense Authorization Act for Fiscal Year 2026.
Tackling Predatory Litigation Funding Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; H.R. 1070 To Exclude from Gross Income Certain Income from Providing Real Property Insurance Following Certain Federally Declared Disasters.
Tackling Predatory Litigation Funding Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: TCJA; Issues lobbied without specific bill number: Third Party Litigation Financing Tax on Any Income Derived from that Kind of Litigation Funding; S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; S. 336 To Exclude from Gross Income Amount Received from State-based Catastrophe Loss Mitigation Programs.
Tackling Predatory Litigation Funding Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Tackling Predatory Litigation Funding Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Tackling Predatory Litigation Funding Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Tackling Predatory Litigation Funding Act
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; H.R. 1070 To Exclude from Gross Income Certain Income from Providing Real Property Insurance Following Certain Federally Declared Disasters.
Issues related to AI (artificial intelligence) in the defense industry; H.R. 4016 - Department of Defense Appropriations Act, 2026; S. 2572 Department of Defense Appropriations Act, 2026.
Issues related to AI (artificial intelligence) in the defense industry; H.R. 4016 - Department of Defense Appropriations Act, 2026; S. 2572 Department of Defense Appropriations Act, 2026.
Issues related to AI (artificial intelligence) in the defense industry; H.R. 4016 - Department of Defense Appropriations Act, 2026; S. 2572 Department of Defense Appropriations Act, 2026.
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
Disaster Mitigation and Tax Parity Act of 2025
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: TCJA; Issues lobbied without specific bill number: Third Party Litigation Financing Tax on Any Income Derived from that Kind of Litigation Funding; S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; S. 336 To Exclude from Gross Income Amount Received from State-based Catastrophe Loss Mitigation Programs.
Legislation adding accounting to STEM definition including the Accounting STEM Pursuit Act (H.R. 2911and S. 3784).
Legislation adding accounting to STEM definition including the Accounting STEM Pursuit Act (H.R. 2911and S. 3784).
Legislation adding accounting to STEM definition including the Accounting STEM Pursuit Act (H.R. 2911and S. 3784).
Litigation Funding Transparency Act of 2026
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Litigation Funding Transparency Act of 2026
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Litigation Funding Transparency Act of 2026
Client: AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS · Firm: CGCN GROUP, LLC
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
Connected Vehicle Security Act of 2026
Client: THE MOTOR & EQUIPMENT MANUFACTURERS ASSOCIATION · Firm: CGCN GROUP, LLC
Issues related to consumer motor vehicle parts; the advancement of repair options for vehicle technology components and systems to improve safety of motor vehicles, auto parts supply chains, and importation; S. 4429 Connected Vehicle Security Act.
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Issues related to medical countermeasures for Acute Radiation Syndrome (ARS).
Issues pertaining to the development of public health emergency medical countermeasures. Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2026 · third_quarter · Q3
Issues related to the nursing workforce, scientific research and health technology.
Issues related to promoting Medicaid program integrity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAI SERVICES COMPANY via CGCN GROUP, LLC
2026 · third_quarter · Q3
Implementation of P.L. 111-31, the Tobacco Control Act; Issues surrounding FDA PMTA and MRTP compliance policies; Issues surrounding tobacco harm reduction; Issues surrounding efforts to prevent youth access to tobacco products; Discussions in support of the regulation of products containing synthetic nicotine and disposable e-cigarettes; Issues surrounding increased scrutiny on FDA/CTP for delayed enforcement; Issues surrounding CBP resources for interdicting massive influx & mislabeling illicit vapes; Issues surrounding retail inspections enforcement limitation; Issues surrounding implementation of P.L. 111-31, the Tobacco Control Act; NPRM for Docket No. FDA-2021-N-1349: Tobacco Product Standard for Menthol in Cigarettes; January 2025 Proposed Rule: Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products; Issues surrounding efforts to prevent youth access to tobacco products; Discussions regarding federal excise taxes and the taxation of tobacco products; Discussions regarding FDA enforcement of flavored disposable e-cigarettes and PMTA transparency.
Discussions concerning the FY 2025 and FY 2026 appropriations bills; provisions related to the FDA regulation of tobacco.
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
Issues surrounding prevention of illicit tobacco, patents, tariffs, duty and customs, Free Trade Agreements (FTAs); HR 1, THE ONE BIG BEAUTIFUL BILL
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
Advocacy related to bladder cancer treatment and blue light cystoscopy, H.R. 8032.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOLSTICE ADVANCED MATERIALS INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to specialty chemical manufacturing.
Issues related to access and trade of manufactured products; Issues related to US export restrictions and sanctions.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
PARKVIEW HEALTH SYSTEM, INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
General health care issues related to hospitals; Lower Costs, More Transparency Act (H.R. 9393).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, White House Office
THE MOTOR & EQUIPMENT MANUFACTURERS ASSOCIATION via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to consumer motor vehicle parts; the advancement of repair options for vehicle technology components and systems to improve safety of motor vehicles, auto parts supply chains, and importation; S. 4429 Connected Vehicle Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to the technology sector and online commerce.
Issues related to consumer safety and privacy.
Issues related to the technology sector and online commerce.
CHANGE & IMPACT, INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to improving access to healthcare and expanding services and resources for those who have a speech impediment; Issues related to intervention research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C3.AI, INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to AI (artificial intelligence) in the defense industry; H.R. 4016 - Department of Defense Appropriations Act, 2026; S. 2572 Department of Defense Appropriations Act, 2026.
Issues related to AI (artificial intelligence) in the defense industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via CGCN GROUP, LLC
2026 · third_quarter · Q3
Access to innovative non-opioid medicines.
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FUJIFILM HOLDINGS AMERICA CORPORATION via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to trade and tariffs.
Issues related to domestic chemical manufacturing.
S.1071 - National Defense Authorization Act for Fiscal Year 2026.
MANUS BIO INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues pertaining to onshoring of biotechnology manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ASSOCIATION FOR COMPETITIVE TECHNOLOGY via CGCN GROUP, LLC
2026 · third_quarter · Q3
Digital trade issues related to competition policy.
House and Senate Antitrust measures; Issues related to AICOA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
ALVOGEN, INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to domestic manufacturing and on-shoring pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
AICPA via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues impacting the accounting and auditing profession; Independence of accounting standard setting.
Legislation adding accounting to STEM definition including the Accounting STEM Pursuit Act (H.R. 2911and S. 3784).
General issues related to multiple areas of the tax code.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENTEK TECHNOLOGY HOLDING, LLC via CGCN GROUP, LLC
2026 · third_quarter · 3A
Battery and battery component manufacturing.
Battery and battery component manufacturing.
Battery and battery component manufacturing.
Filing targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Energy Regulatory Commission (FERC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues lobbied without specific bill number: National Flood Insurance Program
H.R. 7128 Terrorism Risk Insurance
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to healthcare funding, access, and delivery; and issues related to Medicaid financing and reimbursement.
Issues related to healthcare funding, access, and delivery; and issues related to Medicaid financing and reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS KABI USA, LLC via CGCN GROUP, LLC
2026 · third_quarter · Q3
Section 232 investigation into pharmaceuticals and unfair trade practices.
U.S. manufacturing incentives.
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.
EMERGENT BIOSOLUTIONS INC. via CGCN GROUP, LLC
2026 · third_quarter · Q3
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
CARE SOLACE via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to mental healthcare and technology.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
HIGHLAND ELECTRIC FLEETS via CGCN GROUP, LLC
2026 · third_quarter · Q3
Issues related to federal clean school bus programs.
Issues related to federal clean school bus programs.
Issues related to electric grid infrastructure.
Filing targets: Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ENTEK TECHNOLOGY HOLDING, LLC via CGCN GROUP, LLC
2026 · third_quarter · Q3
Battery and battery component manufacturing.
Battery and battery component manufacturing.
Battery and battery component manufacturing.
Filing targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Energy Regulatory Commission (FERC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
PHOTOCURE INC. via CGCN GROUP, LLC
2026 · third_quarter · RR
Advocacy related to bladder cancer treatment and blue light cystoscopy, H.R. 8032.
OTW HOLDINGS LLC via CGCN GROUP, LLC
2026 · third_quarter · RR
Issues related to maternal and infant health.
HEALTHY MOMS, HEALTHY BABIES AMERICA via CGCN GROUP, LLC
2026 · third_quarter · RA
Issues related to maternal and infant health.
HEALTHY MOMS, HEALTHY BABIES AMERICA via CGCN GROUP, LLC
2026 · third_quarter · RR
Issues related to maternal and infant health.
AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS via CGCN GROUP, LLC
2026 · second_quarter · Q2
H.R. 1566 Right to Repair **Issues lobbied without specific bill number:AutonomousVehicles
Issues lobbied without specific bill number: National Flood Insurance Program
S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; H.R. 1070 To Exclude from Gross Income Certain Income from Providing Real Property Insurance Following Certain Federally Declared Disasters.
RAI SERVICES COMPANY via CGCN GROUP, LLC
2026 · second_quarter · Q2
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
Issues surrounding prevention of illicit tobacco, patents, tariffs, duty and customs, Free Trade Agreements (FTAs); HR 1, THE ONE BIG BEAUTIFUL BILL
HEARTLAND ACTION via CGCN GROUP, LLC
2026 · second_quarter · 2T
Issues related to maternal and infant health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE MOTOR & EQUIPMENT MANUFACTURERS ASSOCIATION via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues related to consumer motor vehicle parts; the advancement of repair options for vehicle technology components and systems to improve safety of motor vehicles, auto parts supply chains, and importation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
HIGHLAND ELECTRIC FLEETS via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues related to federal clean school bus programs.
Issues related to electric grid infrastructure.
Issues related to federal clean school bus programs.
Filing targets: Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SOLSTICE ADVANCED MATERIALS INC. via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues related to specialty chemical manufacturing.
Issues related to access and trade of manufactured products; Issues related to US export restrictions and sanctions.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
EMERGENT BIOSOLUTIONS INC. via CGCN GROUP, LLC
2026 · second_quarter · Q2
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
FRESENIUS KABI USA, LLC via CGCN GROUP, LLC
2026 · second_quarter · Q2
Section 232 investigation into pharmaceuticals and unfair trade practices.
U.S. manufacturing incentives.
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.
FUJIFILM HOLDINGS AMERICA CORPORATION via CGCN GROUP, LLC
2026 · second_quarter · Q2
S.1071 - National Defense Authorization Act for Fiscal Year 2026.
Funding for the Public Health Social Services Emergency Fund (PHSSEF) - Biomedical Advanced Research and Development Authority (BARDA); H.R. 10545, the American Relief Act, 2025.
Issues related to trade and tariffs.
PARTNER THERAPEUTICS, INC. via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues pertaining to the development of public health emergency medical countermeasures. Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Issues related to medical countermeasures for Acute Radiation Syndrome (ARS).
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
MANUS BIO INC. via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues pertaining to onshoring of biotechnology manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues related to healthcare funding, access, and delivery; and issues related to Medicaid financing and reimbursement.
Issues related to healthcare funding, access, and delivery; and issues related to Medicaid financing and reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via CGCN GROUP, LLC
2026 · second_quarter · Q2
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Access to innovative non-opioid medicines.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2026 · second_quarter · Q2
Issues related to the nursing workforce, scientific research and health technology.
Issues related to promoting Medicaid program integrity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARKVIEW HEALTH SYSTEM, INC. via CGCN GROUP, LLC
2026 · second_quarter · Q2
General health care issues related to hospitals; Lower Costs, More Transparency Act (H.R. 9393).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, White House Office
2026 · second_quarter · Q2
Issues related to de minimis.
Issues related to organized retail crime.
Issues related to the technology sector and online commerce.
CHANGE & IMPACT, INC. via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues related to improving access to healthcare and expanding services and resources for those who have a speech impediment; Issues related to intervention research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CARE SOLACE via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues related to mental healthcare and technology.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
C3.AI, INC. via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues related to AI (artificial intelligence) in the defense industry.
Issues related to AI (artificial intelligence) in the defense industry; H.R. 4016 - Department of Defense Appropriations Act, 2026; S. 2572 Department of Defense Appropriations Act, 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BINTI via CGCN GROUP, LLC
2026 · second_quarter · 2T
Issues regarding child welfare and technology.
Issues regarding child welfare and technology.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALVOGEN, INC. via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues related to domestic manufacturing and on-shoring pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ASSOCIATION FOR COMPETITIVE TECHNOLOGY via CGCN GROUP, LLC
2026 · second_quarter · Q2
Digital trade issues related to competition policy.
House and Senate Antitrust measures; Issues related to AICOA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AICPA via CGCN GROUP, LLC
2026 · second_quarter · Q2
Issues impacting the accounting and auditing profession; Independence of accounting standard setting.
General issues related to multiple areas of the tax code.
Legislation adding accounting to STEM definition including the Accounting STEM Pursuit Act (H.R. 2911and S. 3784).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENTEK TECHNOLOGY HOLDING, LLC via CGCN GROUP, LLC
2026 · second_quarter · Q2
Battery and battery component manufacturing.
Battery and battery component manufacturing.
Battery and battery component manufacturing.
Filing targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
HEARTLAND ACTION via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues related to maternal and infant health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS KABI USA, LLC via CGCN GROUP, LLC
2026 · first_quarter · Q1
Buy America legislation, tariffs, and tax incentives.
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.
Section 232 investigation into pharmaceuticals and unfair trade practices.
FUJIFILM HOLDINGS AMERICA CORPORATION via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues related to trade and tariffs.
Support for biopharmaceutical manufacturing in the U.S.; Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
S.1071 - National Defense Authorization Act for Fiscal Year 2026.
MANUS BIO INC. via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues pertaining to onshoring of biotechnology manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
EMERGENT BIOSOLUTIONS INC. via CGCN GROUP, LLC
2026 · first_quarter · Q1
Reauthorization of Protecting Americans from All-Hazards Preparedness Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY27 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 Tribal Opioid Response Grant funding for FY27 NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act
Reauthorization of Protecting Americans from All-Hazards Preparedness Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY27 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 Tribal Opioid Response Grant funding for FY27 NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act
2026 · first_quarter · Q1
Issues related to de minimis.
Issues related to consumer safety and privacy.
Issues related to the technology sector and online commerce.
SOLSTICE ADVANCED MATERIALS INC. via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues related to specialty chemical manufacturing.
Issues related to access and trade of manufactured products; Issues related to US export restrictions and sanctions.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
PARKVIEW HEALTH SYSTEM, INC. via CGCN GROUP, LLC
2026 · first_quarter · Q1
General health care issues related to hospitals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTNER THERAPEUTICS, INC. via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues related to medical countermeasures for Acute Radiation Syndrome (ARS).
Issues pertaining to the development of public health emergency medical countermeasures. Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
RAI SERVICES COMPANY via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues surrounding prevention of illicit tobacco, patents, tariffs, duty and customs, Free Trade Agreements (FTAs); HR 1, THE ONE BIG BEAUTIFUL BILL
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
2026 · first_quarter · Q1
Issues related to promoting Medicaid program integrity.
Issues related to the nursing workforce, scientific research and health technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues related to healthcare funding, access, and delivery; and issues related to Medicaid financing and reimbursement.
Issues related to healthcare funding, access, and delivery; and issues related to Medicaid financing and reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE MOTOR & EQUIPMENT MANUFACTURERS ASSOCIATION via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues related to consumer motor vehicle parts; the advancement of repair options for vehicle technology components and systems to improve safety of motor vehicles.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via CGCN GROUP, LLC
2026 · first_quarter · Q1
Access to innovative non-opioid medicines.
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
CHANGE & IMPACT, INC. via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues related to improving access to healthcare and expanding services and resources for those who have a speech impediment; Issues related to intervention research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C3.AI, INC. via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues related to AI (artificial intelligence) in the defense industry.
Issues related to AI (artificial intelligence) in the defense industry; H.R. 4016 - Department of Defense Appropriations Act, 2026; S. 2572 Department of Defense Appropriations Act, 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR COMPETITIVE TECHNOLOGY via CGCN GROUP, LLC
2026 · first_quarter · Q1
House and Senate Antitrust measures; Issues related to AICOA.
Digital trade issues related to competition policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS via CGCN GROUP, LLC
2026 · first_quarter · Q1
H.R. 7128 Terrorism Risk Insurance
H.R. 1566 Right to Repair
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
AICPA via CGCN GROUP, LLC
2026 · first_quarter · Q1
General issues related to multiple areas of the tax code.
Issues impacting the accounting and auditing profession; Independence of accounting standard setting.
Legislation adding accounting to STEM definition including the Accounting STEM Pursuit Act (H.R. 2911and S. 3784).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENTEK TECHNOLOGY HOLDING, LLC via CGCN GROUP, LLC
2026 · first_quarter · Q1
Battery and battery component manufacturing.
Battery and battery component manufacturing.
Battery and battery component manufacturing.
Filing targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
CARE SOLACE via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues related to mental healthcare and technology.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
BINTI via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues regarding child welfare and technology.
Issues regarding child welfare and technology.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALVOGEN, INC. via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues related to domestic manufacturing and on-shoring pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
HIGHLAND ELECTRIC FLEETS via CGCN GROUP, LLC
2026 · first_quarter · Q1
Issues related to federal clean school bus programs.
Issues related to electric grid infrastructure.
Issues related to federal clean school bus programs.
Filing targets: Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
HEARTLAND ACTION via CGCN GROUP, LLC
2026 · first_quarter · RR
Issues related to maternal health.
SOLSTICE ADVANCED MATERIALS INC. via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Issues related to specialty chemical manufacturing.
Issues related to access and trade of manufactured products; Issues related to US export restrictions and sanctions.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
EMERGENT BIOSOLUTIONS INC. via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield forFY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield forFY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act
FUJIFILM HOLDINGS AMERICA CORPORATION via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Support for biopharmaceutical manufacturing in the U.S.; Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Funding for the Public Health Social Services Emergency Fund (PHSSEF) - Biomedical Advanced Research and Development Authority (BARDA); H.R. 10545, the American Relief Act, 2025.
Issues related to domestic chemical manufacturing.
FRESENIUS KABI USA, LLC via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Buy America legislation, tariffs, and tax incentives.
Section 232 investigation into pharmaceuticals and unfair trade practices.
U.S. manufacturing incentives.
KRAFT HEINZ COMPANY via CGCN GROUP, LLC
2025 · fourth_quarter · 4T
Issues related to food quality, pricing, and ingredients.
Issues related to food quality, pricing, and ingredients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
POLYMEDCO, LLC. via CGCN GROUP, LLC
2025 · fourth_quarter · 4T
Issues related to colorectal cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE MOTOR & EQUIPMENT MANUFACTURERS ASSOCIATION via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Issues related to consumer motor vehicle parts; the advancement of repair options for vehicle technology components and systems to improve safety of motor vehicles.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Access to innovative non-opioid medicines.
Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PARKVIEW HEALTH SYSTEM, INC. via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
General health care issues related to hospitals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MANUS BIO INC. via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Issues pertaining to onshoring of biotechnology manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2025 · fourth_quarter · Q4
Issues related to computer industry and privacy.
SHOP SAFE Act and Issues related to trademark liability.
Issues related to consumer safety and privacy.
CHANGE & IMPACT, INC. via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Issues related to improving access to healthcare and expanding services and resources for those who have a speech impediment; Issues related to intervention research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C3.AI, INC. via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Issues related to AI (artificial intelligence) in the defense industry; H.R. 4016 - Department of Defense Appropriations Act, 2026; S. 2572 Department of Defense Appropriations Act, 2026.
Issues related to AI (artificial intelligence) in the defense industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALVOGEN, INC. via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Issues related to domestic manufacturing and on-shoring pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
HIGHLAND ELECTRIC FLEETS via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Issues related to federal clean school bus programs.
Issues related to federal clean school bus programs.
Issues related to electric grid infrastructure.
Filing targets: Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
PARTNER THERAPEUTICS, INC. via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Issues pertaining to the development of public health emergency medical countermeasures. Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
RAI SERVICES COMPANY via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Implementation of P.L. 111-31, the Tobacco Control Act; Issues surrounding FDA PMTA and MRTP compliance policies; Issues surrounding tobacco harm reduction; Issues surrounding efforts to prevent youth access to tobacco products; Discussions in support of the regulation of products containing synthetic nicotine and disposable e-cigarettes; Issues surrounding increased scrutiny on FDA/CTP for delayed enforcement; Issues surrounding CBP resources for interdicting massive influx & mislabeling illicit vapes; Issues surrounding retail inspections enforcement limitation; Issues surrounding implementation of P.L. 111-31, the Tobacco Control Act; NPRM for Docket No. FDA-2021-N-1349: Tobacco Product Standard for Menthol in Cigarettes; January 2025 Proposed Rule: Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products; Issues surrounding efforts to prevent youth access to tobacco products; Discussions regarding federal excise taxes and the taxation of tobacco products; Discussions regarding FDA enforcement of flavored disposable e-cigarettes and PMTA transparency.
AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Issues lobbied without specific bill number: National Flood Insurance Program
H.R. 1566 Right to Repair
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing.
ENTEK TECHNOLOGY HOLDING, LLC via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Battery and battery component manufacturing.
Battery and battery component manufacturing.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
BINTI via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Issues regarding child welfare and technology.
Issues regarding child welfare and technology.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
CARE SOLACE via CGCN GROUP, LLC
2025 · fourth_quarter · Q4
Issues related to mental healthcare and technology.
Filing targets: Agriculture, Dept of (USDA), Education, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2025 · fourth_quarter · Q4
Issues related to the nursing workforce.
Issues related to promoting Medicaid program integrity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the postal industry.
Issues related to organized retail crime.
Issues related to computer industry and privacy.
Issues related to de minimis.
SHOP SAFE Act and Issues related to trademark liability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Support for biopharmaceutical manufacturing in the U.S.; Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Funding for the Public Health Social Services Emergency Fund (PHSSEF) - Biomedical Advanced Research and Development Authority (BARDA); H.R. 10545, the American Relief Act, 2025.
Filing targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
H.R. 1566 Right to Repair **Issues lobbied without specific bill number:AutonomousVehicles
S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; H.R. 1070 To Exclude from Gross Income Certain Income from Providing Real Property Insurance Following Certain Federally Declared Disasters.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Buy America legislation, tariffs, and tax incentives.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Issues lobbied without specific bill number: Third Party Litigation Financing; Issues lobbied without specific bill number: Per- and Polyfluoroalkyl Substances liability; H.R. 1109 Third-Party Litigation Financing; H.R. 2675 Third-Party Litigation Financing; H.R. 3512 Third-Party Litigation Financing; S. 1821 Third-Party Litigation Financing; H.R. 4194 Third-Party Litigation Financing; H.R. 5258 Third-Party Litigation Financing; H.R. 5268 Third-Party Litigation Financing; H.R. 7015 Third-Party Litigation Finacing; S. 3826 Third-Party Litigation Financing.
H.R. 7128 Terrorism Risk Insurance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Implementation of P.L. 111-31, the Tobacco Control Act; Issues surrounding FDA PMTA and MRTP compliance policies; Issues surrounding tobacco harm reduction; Issues surrounding efforts to prevent youth access to tobacco products; Discussions in support of the regulation of products containing synthetic nicotine and disposable e-cigarettes; Issues surrounding increased scrutiny on FDA/CTP for delayed enforcement; Issues surrounding CBP resources for interdicting massive influx & mislabeling illicit vapes; Issues surrounding retail inspections enforcement limitation; Issues surrounding implementation of P.L. 111-31, the Tobacco Control Act; NPRM for Docket No. FDA-2021-N-1349: Tobacco Product Standard for Menthol in Cigarettes; January 2025 Proposed Rule: Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products; Issues surrounding efforts to prevent youth access to tobacco products; Discussions regarding federal excise taxes and the taxation of tobacco products; Discussions regarding FDA enforcement of flavored disposable e-cigarettes and PMTA transparency.
Discussions concerning the FY 2025 and FY 2026 appropriations bills; provisions related to the FDA regulation of tobacco.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Buy America legislation, tariffs, and tax incentives.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Support for biopharmaceutical manufacturing in the U.S.; Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Issues related to domestic chemical manufacturing.
Filing targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Issues related to computer industry and privacy.
SHOP SAFE Act and Issues related to trademark liability.
Issues related to consumer safety and privacy.
Issues related to the postal industry.
Issues related to the technology sector and online commerce.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
U.S. manufacturing incentives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Funding for the Public Health Social Services Emergency Fund (PHSSEF) - Biomedical Advanced Research and Development Authority (BARDA); H.R. 10545, the American Relief Act, 2025.
Issues related to domestic chemical manufacturing.
Filing targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Reauthorization of Protecting Americans from All-Hazards Preparedness Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY27 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 Tribal Opioid Response Grant funding for FY27 NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act
Reauthorization of Protecting Americans from All-Hazards Preparedness Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY27 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 Tribal Opioid Response Grant funding for FY27 NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Issues related to the postal industry.
Issues related to organized retail crime.
SHOP SAFE Act and Issues related to trademark liability.
Issues related to the technology sector and online commerce.
Issues related to the technology sector and online commerce.
Issues related to computer industry and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Implementation of P.L. 111-31, the Tobacco Control Act; Issues surrounding FDA PMTA and MRTP compliance policies; Issues surrounding tobacco harm reduction; Issues surrounding efforts to prevent youth access to tobacco products; Discussions in support of the regulation of products containing synthetic nicotine and disposable e-cigarettes; Issues surrounding increased scrutiny on FDA/CTP for delayed enforcement; Issues surrounding CBP resources for interdicting massive influx & mislabeling illicit vapes; Issues surrounding retail inspections enforcement limitation; Issues surrounding implementation of P.L. 111-31, the Tobacco Control Act; NPRM for Docket No. FDA-2021-N-1349: Tobacco Product Standard for Menthol in Cigarettes; January 2025 Proposed Rule: Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products; Issues surrounding efforts to prevent youth access to tobacco products; Discussions regarding federal excise taxes and the taxation of tobacco products; Discussions regarding FDA enforcement of flavored disposable e-cigarettes and PMTA transparency.
Discussions concerning the FY 2025 and FY 2026 appropriations bills; provisions related to the FDA regulation of tobacco.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues lobbied without specific bill number: National Flood Insurance Program
Issues lobbied without specific bill number: Climate Disaster Mitigation, Resilience, and Recovery; Issues lobbied without specific bill number: Climate and Weather Prediction; Issues lobbied without specific bill number: Wildland Fire Mitigation and Management Commission Recommendations.
Issues lobbied without specific bill number: TCJA; Issues lobbied without specific bill number: Third Party Litigation Financing Tax on Any Income Derived from that Kind of Litigation Funding; S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; S. 336 To Exclude from Gross Income Amount Received from State-based Catastrophe Loss Mitigation Programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield forFY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield forFY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Issues related to trade and tariffs.
S.1071 - National Defense Authorization Act for Fiscal Year 2026.
Filing targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to de minimis.
Issues related to organized retail crime.
Issues related to the postal industry.
Issues related to the technology sector and online commerce.
Issues related to the technology sector and online commerce.
Issues related to the technology sector and online commerce.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues surrounding prevention of illicit tobacco, patents, tariffs, duty and customs, Free Trade Agreements (FTAs); HR 1, THE ONE BIG BEAUTIFUL BILL
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.
Discussions concerning the FY 2025 and FY 2026 appropriations bills; provisions related to the FDA regulation of tobacco.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues lobbied without specific bill number: Climate Disaster Mitigation, Resilience, and Recovery; Issues lobbied without specific bill number: Climate and Weather Prediction; Issues lobbied without specific bill number: Wildland Fire Mitigation and Management Commission Recommendations.
Issues lobbied without specific bill number: TCJA; Issues lobbied without specific bill number: Third Party Litigation Financing Tax on Any Income Derived from that Kind of Litigation Funding; S.1821 - Tackling Predatory Litigation Funding Act; H.R.3512 - Tackling Predatory Litigation Funding Act; S. 336 To Exclude from Gross Income Amount Received from State-based Catastrophe Loss Mitigation Programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE